Jeff Stark, MD

Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.

At AAD 2025, UCB will present 5-year data for Bimzelx in psoriasis, highlighting rapid, durable responses and long-term safety for patients.

The new dose offers a more tailored and convenient option for patients with inflammatory conditions.

The pivotal BE HEARD trials demonstrated bimekizumab’s efficacy, showing meaningful improvements over placebo in HS patients.

The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.